Actuate Q3 10-Q: $2.1M Cash, Going-Concern Doubt, Over-Allotment Adds $1.5M
ACTU is trading near its 52-week low of $0.283 (0.8% above the low).
Summary
Actuate closed Q3 with $2.1 million in cash and explicit going-concern doubt, relying on an October offering that netted $11.76 million after the over-allotment was exercised November 13. Two Nasdaq listing deficiencies remain unresolved.
Key Events · Earnings and Guidance · ACTU
-
Cash Drops to $2.1 Million
Cash and cash equivalents fell to $2,101,816 at September 30, 2026 from $13,159,423 at December 31, 2025, leaving a working capital deficit of $974,694.
-
Going-Concern Doubt Stated
Management concluded there is substantial doubt about the company's ability to continue as a going concern, saying cash plus the October offering will not fund operations for at least one year without more capital.
-
October Offering Fully Closed
The over-allotment was exercised November 13, 2026 for 4,647,885 additional shares and 2,323,942 warrants, adding $1,534,499 net and bringing total net proceeds to $11,764,494 on 35,633,785 shares and 17,816,892 warrants.
-
Two Nasdaq Deficiencies Pending
The $50 million MVLS shortfall must be cured by January 11, 2027, and the $1.00 minimum bid notice by April 26, 2027; the company may pursue a transfer to the Nasdaq Capital Market or a reverse stock split.
Analysis · ACTU · Life Sciences
Actuate ended Q3 with just $2.1 million in cash and a $974,694 working capital deficit, and management states plainly that cash plus the October offering will not fund operations for a year — substantial doubt about going concern. The October offering, now fully closed with the over-allotment exercised November 13, brings net proceeds to $11.76 million and buys time, but at a brutal cost: shares were sold at $0.355 with warrants struck at $0.45, far below the $1.90+ levels the company raised at earlier this year. Layered on top are two Nasdaq deficiencies — the $50 million MVLS shortfall (cure deadline January 11, 2027) and the $1.00 minimum bid notice (April 26, 2027) — with a reverse split explicitly on the table. The clinical story (elraglusib's Phase 2 mPDAC win) is intact, but the balance sheet, not the data, now sets the terms.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $0.28 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.